Skip to content

ZNN Bactiguard Cephalomedullary Nails PMCF Study

Post-Market Clinical Follow-up Study on the ZNN™ Bactiguard ® Cephalomedullary Nails (Implants and Instrumentation). A Multicenter, Prospective, Consecutive Series

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05362864
Enrollment
149
Registered
2022-05-05
Start date
2023-01-23
Completion date
2025-12-17
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femoral Shaft Fracture, Osteotomy, Sub-trochanteric Fractures, Trochanteric Fractures

Keywords

Bactiguard

Brief summary

This is a multicenter, prospective, Post-market Clinical Follow-up (PMCF) Study on the ZNN Bactiguard Cephalomedullary Nails. The objective of this study is to collect data confirming the safety, performance, and clinical benefit of the study device and instrumentation when used for the temporary internal fixation and stabilization of trochanteric, sub-trochanteric or shaft femoral fractures and osteotomies. This is a CE-marked device already available on the market and the aim of the study is to comply with the post-market surveillance requirements.

Detailed description

This study is a multicentre, prospective, post-market clinical follow-up study on the Zimmer Natural Nail (ZNN) Bactiguard Cephalomedullary Nails. The primary endpoint for this study is the assessment of performance by analyzing fracture/osteotomy healing within 12 months after fracture fixation. Radiological fracture healing is defined as bridging callus on at least three of the four cortices on the AP and lateral radiographs and clinically as full weight-bearing without pain. The secondary endpoint is the assessment of safety, clinical benefit, and postop fracture-related infection (FRI). Safety will be evaluated by recording and analyzing the incidence and frequency of complications and adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified. Clinical benefit will be assessed by recording patient-reported outcome measures (PROMs). FRIs will be classified according to the updated diagnostic algorithm defined by the FRI Consensus Group. Data will be collected at 6 weeks, 3 months, 6 months and 1 year after fracture fixation. The study will enroll patients implanted with the Zimmer Natural Nail Bactiguard Cephalomedullary Nail according to the approved/cleared indications. The sample size for this study is 150 study cases, and up to 10 sites in EMEA will participate.

Interventions

PROCEDUREFracture fixation via Intramedullary Nailing

Fixation of trochanteric, sub-trochanteric, and shaft fractures and osteotomies.

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients 18 years or older. * Patient must have a signed EC approved informed consent. * Patient must have a monolateral or bilateral trochanteric, sub-trochanteric, or shaft fracture requiring surgical intervention or osteotomy and be eligible for fixation by intramedullary nailing. * Patient has been or is scheduled to be treated with the ZNN Bactiguard System Cephalomedullary Nail. * Patient must be able and willing to complete the protocol required follow-up. * Patients capable of understanding the surgeon's explanations and following his instructions.

Exclusion criteria

* Skeletally immature patients * Medullary canal obliterated by a previous fracture or tumor * Bone shaft having excessive bow or a deformity * Lack of bone substance or bone quality, which makes stable seating of the implant impossible * All concomitant diseases that can impair the operation, functioning or the success of the implant * Insufficient blood circulation * Infection * Patient is unwilling or unable to give consent. * Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, subject with alcohol/drug addiction, known to be pregnant or breastfeeding). * Patient anticipated to be non-compliant and/or likely to have problems complying with the follow-up program (e.g. patient with no fixed address, long-distance, plans to move during course of study).

Design outcomes

Primary

MeasureTime frameDescription
Performance of the study device by analyzing fracture/osteotomy healing at 12 months after fracture fixation.12 months after fracture fixationPerformance will be assessed by analyzing fracture/osteotomy healing at 12 months after fracture fixation. Fracture healing will be assessed clinically and radiologically: * Radiological fracture healing is defined as bridging callus on at least three of the four cortices on the AP. and lateral radiographs * Clinical fracture healing is defined as full weight-bearing without pain.

Secondary

MeasureTime frameDescription
Safety assessment by recording and analyzing incidence and frequency of adverse events.6 weeks and 3, 6, and 12 months after fracture fixationRecording and analyzing incidence and frequency of adverse events.
Oxford Hip Score3, 6, and 12 months after fracture fixationPatient-Reported Outcome Measures (PROMs) that document hip function and pain. It's used as a surrogate to assess function and pain of the operated limb.
EQ-5D Health Questionnaire3, 6, and 12 months after fracture fixationPatient-reported outcome completed by the patient. It assesses the general health status of the patient and it can be used to derive a quality of life index used for health economics considerations.
Rate of fracture-related infections6 weeks and 3, 6, and 12 months after fracture fixationFracture-related infections are diagnosed in accordance with the algorithm described in M McNally, G Govaert, M Dudareva, M Morgenstern, W J Metsemakers, EFORT Open Rev 2020;5:614-619.

Countries

France, Spain

Contacts

STUDY_DIRECTOREmilie Rohmer

Zimmer Biomet

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026